HR (estrogen receptor α, ER+ and/or progesterone receptor, PR+)-positive breast cancer is consisted of 65–80% of all breast cancers, which are routinely managed by 5 years of endocrine therapy that is extended up to 10 years in recent years [8–10]. This evidence concerns the gene ESR1 and breast cancer.